Update shared on23 Sep 2025
Fair value Decreased 1.61%Despite encouraging Phase III trial data for bemarituzumab in gastric cancer, which bolsters near-term commercial outlooks and regulatory momentum in China, Zai Lab’s consensus analyst price target saw only a slight downward adjustment from $56.31 to $55.41.
Analyst Commentary
- Positive Phase III FORTITUDE-101 trial data for bemarituzumab in first-line FGFR2b+ gastric cancer.
- The drug, developed by Amgen, met its primary endpoint, strengthening clinical credibility.
- Zai Lab holds Greater China rights to bemarituzumab and has participated in key studies.
- Bullish analysts expect the positive trial data to accelerate regulatory submission in China.
- Upward price target revision reflects increased confidence in near-term commercial prospects.
What's in the News
- Final analysis of Phase 3 FORTITUDE-101 trial for bemarituzumab in first-line gastric cancer showed attenuated survival benefit versus earlier interim results; regulatory submission will await results from FORTITUDE-102, expected by end of 2025 or first half of 2026.
- Hong Kong Department of Health approved TIVDAK for recurrent or metastatic cervical cancer after chemotherapy; product is under regulatory review in mainland China, with Zai Lab holding exclusive Greater China commercialization rights.
- China NMPA granted Innovative Medical Device Designation for TTFields in pancreatic cancer, enabling expedited regulatory review and approval.
- Zai Lab reaffirmed full-year 2025 revenue guidance of $560 million to $590 million.
- Interim analysis from FORTITUDE-101 showed bemarituzumab plus chemotherapy met primary endpoint of overall survival in FGFR2b+ gastric/gastroesophageal junction cancer, with statistically significant and clinically meaningful improvement over placebo plus chemotherapy.
Valuation Changes
Summary of Valuation Changes for Zai Lab
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from $56.31 to $55.41.
- The Future P/E for Zai Lab has fallen slightly from 37.81x to 36.66x.
- The Net Profit Margin for Zai Lab remained effectively unchanged, moving only marginally from 16.74% to 16.83%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.